Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 69 Published: April 29, 2022 Report Code: GMDGDHC22154IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech

Bronchopulmonary dysplasia (BPD) can occur with multiple symptoms including tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting), and bluish skin color. The Treatment of BPD includes bronchodilators, diuretics, and antibiotics.

The Bronchopulmonary Dysplasia pipeline market research report provides an overview of the Bronchopulmonary Dysplasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Bronchopulmonary Dysplasia Pipeline Drugs Market by Key Targets

Some of the targets of the Bronchopulmonary Dysplasia pipeline drugs market are Pulmonary Surfactant Associated Protein D, Retinoic Acid Receptor Alpha, Retinoic Acid Receptor Beta, Retinoic Acid Receptor Gamma, Thioredoxin, Apelin Receptor, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Insulin Like Growth Factor 1 Receptor, and Insulin Like Growth Factor Binding Protein 3.

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Targets

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Bronchopulmonary Dysplasia Pipeline Drugs Market

Some of the key mechanisms of action of the Bronchopulmonary Dysplasia pipeline drugs market are Pulmonary Surfactant Associated Protein D Replacement, Retinoic Acid Receptor Alpha Agonist, Retinoic Acid Receptor Beta Agonist, Retinoic Acid Receptor Gamma Agonist, Thioredoxin Activator, Apelin Receptor Agonist, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Insulin Like Growth Factor 1 Receptor Agonist, and Insulin Like Growth Factor Binding Protein 3 Inhibitor.

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Mechanisms of Action

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Bronchopulmonary Dysplasia Pipeline Drugs Market

The key routes of administration in the Bronchopulmonary Dysplasia pipeline drugs market are inhalational, intratracheal, intravenous, intracerebral, oral, ophthalmic, and subcutaneous.

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Routes of Administration

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Bronchopulmonary Dysplasia Pipeline Drugs Market

The molecule types in the Bronchopulmonary Dysplasia pipeline drugs market are small molecule, cell therapy, recombinant protein, antisense oligonucleotide, biologic, monoclonal antibody, and synthetic peptide.

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Molecule Types

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Bronchopulmonary Dysplasia Pipeline Drugs Market Companies

Some of the key companies in the Bronchopulmonary Dysplasia pipeline drugs market are Radikal Therapeutics Inc, MediPost Co Ltd, Meridigen Biotech Co Ltd, Velvio GmbH, Advent Therapeutics Inc, Airway Therapeutics Inc, APIE Therapeutics Inc, Ayuvis Research Inc, Boehringer Ingelheim International GmbH, and Chiesi Farmaceutici SpA. Radikal Therapeutics Inc has the highest pipeline products.

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Key Companies

Bronchopulmonary Dysplasia Pipeline Drugs Market, by Key Companies

To know more about key companies, download a free report sample

Market Report Overview

Key Targets Pulmonary Surfactant Associated Protein D, Retinoic Acid Receptor Alpha, Retinoic Acid Receptor Beta, Retinoic Acid Receptor Gamma, Thioredoxin, Apelin Receptor, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Insulin Like Growth Factor 1 Receptor, and Insulin Like Growth Factor Binding Protein 3
Key Mechanisms of Action Pulmonary Surfactant Associated Protein D Replacement, Retinoic Acid Receptor Alpha Agonist, Retinoic Acid Receptor Beta Agonist, Retinoic Acid Receptor Gamma Agonist, Thioredoxin Activator, Apelin Receptor Agonist, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Insulin Like Growth Factor 1 Receptor Agonist, and Insulin Like Growth Factor Binding Protein 3 Inhibitor
Key Routes of Administration Inhalational, Intratracheal, Intravenous, Intracerebral, Oral, Ophthalmic, and Subcutaneous
Key Molecule Types Small Molecule, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Biologic, Monoclonal Antibody, and Synthetic Peptide
Key Companies Radikal Therapeutics Inc, MediPost Co Ltd, Meridigen Biotech Co Ltd, Velvio GmbH, Advent Therapeutics Inc, Airway Therapeutics Inc, APIE Therapeutics Inc, Ayuvis Research Inc, Boehringer Ingelheim International GmbH, and Chiesi Farmaceutici SpA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • Reviews of pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • Evaluation of Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Advent Therapeutics Inc

Airway Therapeutics Inc

APIE Therapeutics Inc

Ayuvis Research Inc

Boehringer Ingelheim International GmbH

Chiesi Farmaceutici SpA

Exo Biologics SA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Pharmaceuticals

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Trimunocor Ltd

Velvio GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchopulmonary Dysplasia – Overview

Bronchopulmonary Dysplasia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bronchopulmonary Dysplasia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchopulmonary Dysplasia – Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Airway Therapeutics Inc

APIE Therapeutics Inc

Ayuvis Research Inc

Boehringer Ingelheim International GmbH

Chiesi Farmaceutici SpA

Exo Biologics SA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Pharmaceuticals

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Trimunocor Ltd

Velvio GmbH

Bronchopulmonary Dysplasia – Drug Profiles

APT-D – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVR-48 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologics for Autoimmune Disorders, Bronchopulmonary Dysplasia, Inflammation and Injuries – Drug Profile

Product Description

Mechanism Of Action

History of Events

CFMEV-132 – Drug Profile

Product Description

Mechanism Of Action

Drugs for Bronchopulmonary Dysplasia – Drug Profile

Product Description

Mechanism Of Action

mecasermin rinfabate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia – Drug Profile

Product Description

Mechanism Of Action

History of Events

NVP-13 – Drug Profile

Product Description

Mechanism Of Action

NVP-19 – Drug Profile

Product Description

Mechanism Of Action

perfluorooctyl bromide – Drug Profile

Product Description

Mechanism Of Action

pioglitazone + B-YL – Drug Profile

Product Description

Mechanism Of Action

Pneumostem – Drug Profile

Product Description

Mechanism Of Action

History of Events

R-801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

R-901 – Drug Profile

Product Description

Mechanism Of Action

History of Events

R-908 – Drug Profile

Product Description

Mechanism Of Action

Recombinant Surfactant Associated Protein D Replacement for Bronchopulmonary Dysplasia and Lung Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

SX-576 – Drug Profile

Product Description

Mechanism Of Action

History of Events

tiotropium bromide – Drug Profile

Product Description

Mechanism Of Action

UMC-11901 – Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate – Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate – Drug Profile

Product Description

Mechanism Of Action

History of Events

zelpultide alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

Bronchopulmonary Dysplasia – Dormant Projects

Bronchopulmonary Dysplasia – Discontinued Products

Bronchopulmonary Dysplasia – Product Development Milestones

Featured News & Press Releases

Mar 31, 2022: Airway Therapeutics announces first patient dosed in phase 1b trial of AT-100 in preterm infants at risk for Bronchopulmonary Dysplasia (BPD)

Mar 26, 2021: Airway Therapeutics announces FDA acceptance of IND for AT-100 in preterm infants at risk for bronchopulmonary dysplasia (BPD)

Aug 23, 2019: Medipost’s Pneumostem gets FDA’s fast-track designation

May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial

Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.

Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia

Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer

May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung

Aug 12, 2014: MediPost, lung disease stem cell treatment drug ‘Pneumostem’ application for US clinical trial

Jul 29, 2014: Lung disease stem cell drug designated ‘orphan drug in development stage’

Feb 06, 2014: Stem cells to treat lung disease in preterm infants

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem

May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Bronchopulmonary Dysplasia – Pipeline by Advent Therapeutics Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by Airway Therapeutics Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by APIE Therapeutics Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by Ayuvis Research Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by Boehringer Ingelheim International GmbH, 2022

Bronchopulmonary Dysplasia – Pipeline by Chiesi Farmaceutici SpA, 2022

Bronchopulmonary Dysplasia – Pipeline by Exo Biologics SA, 2022

Bronchopulmonary Dysplasia – Pipeline by Insmed Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by MediPost Co Ltd, 2022

Bronchopulmonary Dysplasia – Pipeline by Meridigen Biotech Co Ltd, 2022

Bronchopulmonary Dysplasia – Pipeline by Orphanix GmbH, 2022

Bronchopulmonary Dysplasia – Pipeline by Radikal Therapeutics Inc, 2022

Bronchopulmonary Dysplasia – Pipeline by Syntrix Pharmaceuticals, 2022

Bronchopulmonary Dysplasia – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Bronchopulmonary Dysplasia – Pipeline by The Cell Factory BVBA, 2022

Bronchopulmonary Dysplasia – Pipeline by Trimunocor Ltd, 2022

Bronchopulmonary Dysplasia – Pipeline by Velvio GmbH, 2022

Bronchopulmonary Dysplasia – Dormant Projects, 2022

Bronchopulmonary Dysplasia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Some of the targets of the Bronchopulmonary Dysplasia pipeline drugs market are Pulmonary Surfactant Associated Protein D, Retinoic Acid Receptor Alpha, Retinoic Acid Receptor Beta, Retinoic Acid Receptor Gamma, Thioredoxin, Apelin Receptor, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Insulin Like Growth Factor 1 Receptor, and Insulin Like Growth Factor Binding Protein 3.

Some of the mechanisms of action of the Bronchopulmonary Dysplasia pipeline drugs market are Pulmonary Surfactant Associated Protein D Replacement, Retinoic Acid Receptor Alpha Agonist, Retinoic Acid Receptor Beta Agonist, Retinoic Acid Receptor Gamma Agonist, Thioredoxin Activator, Apelin Receptor Agonist, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Insulin Like Growth Factor 1 Receptor Agonist, and Insulin Like Growth Factor Binding Protein 3 Inhibitor.

The routes of administration in the Bronchopulmonary Dysplasia pipeline drugs market are inhalational, intratracheal, intravenous, intracerebral, oral, ophthalmic, and subcutaneous.

The molecule types in the Bronchopulmonary Dysplasia pipeline drugs market are small molecule, cell therapy, recombinant protein, antisense oligonucleotide, biologic, monoclonal antibody, and synthetic peptide.

Some of the key companies in the Bronchopulmonary Dysplasia pipeline drugs market are Radikal Therapeutics Inc, MediPost Co Ltd, Meridigen Biotech Co Ltd, Velvio GmbH, Advent Therapeutics Inc, Airway Therapeutics Inc, APIE Therapeutics Inc, Ayuvis Research Inc, Boehringer Ingelheim International GmbH, and Chiesi Farmaceutici SpA.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.